

12/18/2020

Dear Resident and/or Representatives,

Please find enclosed in this packet the consent form that will be necessary for your loved one to receive the COVID vaccine. The vaccine will not be provided by Sagepoint's long standing pharmacy partner and instead will be provided by Walgreens pharmacy as required by federal agencies. As many media outlets have reported, no recipients will be charged for the vaccine. You will, however, likely see a charge to your loved ones Medicare B services for ancillary supplies and the administration of the vaccine by the federally approved pharmacy which, in this instance is Walgreens. We have included as much detail about the vaccine as has been made available to us. Included in this packet is the consent form, frequently asked questions and some details on the Pfizer vaccine. As of this time, we have not been informed if we will receive the Pfizer or Moderna vaccine. We further do not have any additional information from Moderna as they have just completed the FDA review and approval process. Please do not hesitate to follow the CDC (Center for Disease Control) as they are routinely posting updates on vaccines for COVID-19.

We have attached the contact information, (301-934-1900 ext. 487) for you to reach out to your provider/attending physician if you have any additional questions or concerns. Please leave a voicemail with as much detail as reasonable and contact information for a return call. You may mail the signed consent form back to us; however, this is not required. We will be making phones call next week to confirm your consent for administration of the vaccine, assuming you are the representative on file to speak on behalf of a resident that is not able to make their own medical decisions. Otherwise we will, as required by law, speak to the resident for consent.

While we do not have a date for vaccine administration yet, we are collecting this consent now in order to be ready to support the distribution and administration of the vaccine as soon as it becomes available. As of the information we have to date, Walgreens is limited under their current contract to arriving onsite no more than three times to administer the vaccine. As we know the vaccine requires two doses, so we are expected to have the necessary mandated documents on file in order to support vaccine administration in a limited window. In order to assist in expediting answers, please direct your questions to the appropriate person. If your questions are logistics of the distribution of the vaccine, please do not hesitate to reach out to us directly. Your Unit Managers will be informed of the distribution plans. If your questions are related to the vaccine and medical information such as side effects or other concerns, they should be directed to the physicians and nurse practitioner at 301-934-1900 ext. 487.

Finally, as of this time, the vaccine will be administered to skilled nursing facility residents and healthcare workers only. We have not received any information on the administration of the vaccine to assisted living residents however we continue to advocate to make it available to them as soon as possible.

Thank you in advance. We are all very relieved to finally have this opportunity to help protect the residents. We have lobbied vigorously to ensure nursing home residents were not left out of the vaccination programs as priority one. Please take full advantage of the historic event and offer your loved one the best opportunity to stem the rising curve of this global pandemic.

Best Regards,

Andrea S. Dwyer, CEO, NHA, MBA

Sagepoint Senior-Living Services

Vaccine Administration Record (VAR) Informed Consent for Vaccination in Long Term Care Facility (LTCF)



SEC	TION A-1 Please print clearly.			
	name:Last name:			
Date	of birth: Age: Gender: □Female □Male Phone: 301-934-1900			
LTC	Name: Sagepoint Senior Living Services Address: 10200 Laplata Rd Laplata State: MD ZIP code: 20646 Patient Email address:			
City	Laplata State: MD ZIP code: 20646 Patient Email address:			
considered appropried the to satisfy considered appropried to satisfy considered and considered appropried the to satisfy considered appropried that the considered appropried the considered appropried that the considered appropried to the considered appropried that the considered appropried to	TION A-2 I certify that I am: (a) the patient and at least 18 years of age; (b) the legal guardian of the patient; sent on behalf of the patient where the patient is not otherwise competent or unable to consent by give my consent to Walgreens or Duane Reade and the licensed healthcare professional admicable (each an "applicable Provider"), to administer the vaccine(s)) I have requested above. I understant lict all possible side effects or complications associated with receiving vaccine(s). I understand the risks a above vaccine(s) and have received, read and/or had explained to me the EUA Fact Sheet on the receive. I also acknowledge that I have had a chance to ask questions and that such question faction. Further, I acknowledge that I have had a chance to ask questions and that such question faction. Further, I acknowledge that I have head a chance to ask questions and that such question faction. Further, I acknowledge that I have been advised that the patient should remain near the reveal of approximately 15 minutes after administration. On behalf of the patient, the patient esentatives, I hereby release and hold harmless each applicable Provider, its staff, agents, succisidiaries, officers, directors, contractors and employees from any and all liabilities or claims whether known of the vaccine of the patient of the patient of the vaccine of the patient of the vaccine of the patient of the vaccine of the patient of the patient of the patient of the patient of the vaccine of the patient of the vaccine of the patient of the patient of the vaccine of the patient of the patient of the patient of the vaccine of the patient of the p	inistering and that it and benefit vaccine (so were expected and the stry") and expected and the stry") and expected and the stry ex	the vision of th	accine, as possible to ociated with ave elected ered to my ocation for personal affiliates, and out of, in ate's health to the State Government ocenter for orting, or to depending form ("Optice State HIE realthcare -Out Form. I, by signing tate HIE, or m. Unless I y permission plicable. Is closures of er authorize g HIV), and e, Medicaid, ditems and spect to the ding copays, yered by my
ins	urance benefits. I understand that any payment for which I am imalicially responsible is due at the	av disclos	e vou	vaccination
	ormation from this visit for public health purposes and will send this information to the Medical Direct ormation from this visit for public health purposes and will send this information to the Medical Direct CF identified above. If you are an employee of the LTCF, Walgreens will send your vaccination information to you			
LT Pri	or identified above. If you are an employee of the ETCF, waigreens will solld you vaccination in manual to you the Name:Patient/Authorized Person signature:	Date		
81:	CTION B-1 SCREENING QUESTIONS. The following questions will help us determine your eligibility to be vaccina	led today. ☐ Yes	□No	□ Don't know
1.	Do you feel sick today? Do you have any health conditions, such as heart disease, diabetes or asthma?			□ Don't know
2	If yes, please list: Do you have allergies to latex, medications, food or vaccines (examples: eggs, bovine protein, gelatin, gentamicin, polymyxin,	ПУрс	□ No	□ Don't know
3.	neomycin, phenol, yeast or thimerosal)? If yes, please list:	-		
4.	Have you ever had a reaction after receiving a vaccination, including fainting or feeling dizzy?			□ Don't know □ Don't know
5.	Have you ever had a seizure disorder for which you are on seizure medication(s), a brain disorder, Guillain-Barré syndrome (a condition that causes paralysis) or other nervous system problem?			
6.	For women: Are you pregnant or considering becoming pregnant in the next month?	⊔ Yes	□ 1/10	□ Don't know

A REPORT OF THE PROPERTY OF TH	tient/LTCF Representative:							
Non-Medicare: Pharmacy Card Medical Card Medicare Part B Medicare Number: Medicare Number: Medicare Number: Medicare Olani Number for cords districted earlier to accomplete Date Medicare Olani Number for cords districted earlier to accomplete Date Medicare Olani Number for cords districted earlier to accomplete Date Medicare Olani Number for cords districted earlier to accomplete Date Medicare Part B Medicare Part								
Insurance Plan/Plan ID: Member/Recipiont ID #:	ease ensure to record BOTH	pharmacy AND medical	l insurance informa	tion since t	here are multip	ole ways immunizations c	an be billed	l at Walgreens.
Member/Recipient ID #: RX PCN:	Non-Medicare:	Pharmacy Card		Medica	l Card	Medicar	e;	Medicare Part B
RX BIN:	Insurance Plan/Plan ID:							
RX PCN: N/A	Member/Recipient ID #:					*Medicare Claim N	umber for card	is distributed earlier than 20°
Group Number: the patient the cardholder?	RX BIN:			N	Ά			
the patient the cardholder?	RX PCN:			N/	A			
HEALTHCARE PROVIDER ONLY	Group Number:							
HEALTHCARE PROVIDER ONLY	the patient the cardholder?	☐ Yes ☐ No						
HEALTHCARE PROVIDER ONLY Tomplete BEFORE vaccine administration I have reviewed the Patient Information and Screening Questions. I have verified that this is the vaccine requested by the patient. This vaccine is appropriate for this patient based on the Age Guidelines and Other Guidelines provided by federal and/or state regulations and company policies. 3a. Does this patient have a high-risk medical condition? If yes, please istmedical condition(s): The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below. Initial here: I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. Initial here: I have reviewed the Screening Questions and answors. I provided a EUA Fact Sheet to the patient or the LTCF representative. Initial here: Ini	·		MAIDDANAY and so	lationahin:				
Initial here: I have reviewed the Patient Information and Screening Questions. I have verified that this is the vaccine requested by the patient. Initial here: I have verified that this is the vaccine requested by the patient. Initial here: I his vaccine is appropriate for this patient based on the Age Guidelines and Other Guidelines provided by federal and/or state regulations and company policies. 3a. Does this patient have a high-risk medical condition? I have verified the verified the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below. I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. I have reviewed the Screening Questions and answers. I provided a EUA Fact Sheet to the patient or the LTCF representative. I provided a EUA Fact Sheet to the patient or the LTCF representative. SECTION F Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published or Dose 2 Clinician's signature: Title: f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:	io, please provide cardholde	rs name, date of birth (N	IIWI/DD/YYY) and re	iationsnip:				
Initial here: I have reviewed the Patient Information and Screening Questions. I have verified that this is the vaccine requested by the patient. Initial here: I have verified that this is the vaccine requested by the patient. Initial here: This vaccine is appropriate for this patient based on the Age Guidelines and Other Guidelines provided by federal and/or state regulations and company policies. 3a. Does this patient have a high-risk medical condition? If yes please list medical condition(s): The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below. Initial here: I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. I have reviewed the Screening Questions and answers. Initial here: I provided a EUA Fact Sheet to the patient or the LTCF representative. Initial here: I provided a EUA Fact Sheet to the patient or the LTCF representative. SECTION F Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published or Dose 2 Clinician's name (print): Clinician's signature: Title: f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:								
I have reviewed the Patient Information and Screening Questions. I have verified that this is the vaccine requested by the patient. This vaccine is appropriate for this patient based on the Age Guidelines and Other Guidelines provided by federal and/or state regulations and company policies. 3a. Does this patient have a high-risk medical condition? Tyes Disability The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: Initia			HEA	LTHCAR	E PROVIDE	R ONLY		
I have verified that this is the vaccine requested by the patient. This vaccine is appropriate for this patient based on the Age Guidelines and Other Guidelines provided by federal and/or state regulations and company policies. 3a. Does this patient have a high-risk medical condition? If yes, please list medical condition(s): The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below. Initial here: SECTIONE Complete DURING the patient interaction I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. Initial here: I have reviewed the Screening Questions and answers. I provided a EUA Fact Sheet to the patient or the LTCF representative. SECTIONE Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published or Clinician's name (print): Clinician's signature: Title: f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:	complete <u>BEFORE</u> vaccine	administration						
I have verified that this is the vaccine requested by the patient. This vaccine is appropriate for this patient based on the Age Guidelines and Other Guidelines provided by federal and/or state regulations and company policies. 3a. Does this patient have a high-risk medical condition? Ityes, please list medical condition(s): The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot# and Expiration Date in the field below. SECTION E Complete DURING the patient interaction I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. Initial here: I have reviewed the Screening Questions and answers. I provided a EUA Fact Sheet to the patient or the LTCF representative. SECTION F Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published or Date in the ITCH. Clinician's signature: Title: f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:			ening Questions.					Initial here:
This vaccine is appropriate for this patient based on the Age Guidelines and Other Guidelines provided by federal and/or state regulations and company policies. 3a. Does this patient have a high-risk medical condition? If yes, please list medical condition(s): The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below. Initial here: SECTION E Complete DURING the patient interaction I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. Initial here: I have reviewed the Screening Questions and answers. I provided a EUA Fact Sheet to the patient or the LTCF representative. SECTION F Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published or Dose 2 Clinician's name (print): Clinician's signature: Title: f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:			ov the patient.					Initial here:
state regulations and company policies. 3a. Does this patient have a high-risk medical condition? If yes, please list medical condition(s): The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot# and Expiration Date in the field below. Initial here: SECTION E Complete DURING the patient interaction I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. Initial here: I have reviewed the Screening Questions and answers. I provided a EUA Fact Sheet to the patient or the LTCF representative. Initial here: I provided a EUA Fact Sheet to the patient or the LTCF representative. SECTION F Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published or Dose 2 Clinician's name (print): Clinician's signature: Title: f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:							- 4-	
3a. Does this patient have a high-risk medical condition? If yes, please list medical condition(s):			i the Age Guidelin i	es and Otr	ier Guidelines	provided by lederal and/o	1	IIIIIIdi Here
If yes, please list medical condition(s): The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here: I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below. Initial here: SECTION E Complete DURING the patient interaction I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. Initial here: I have reviewed the Screening Questions and answers. Initial here: I provided a EUA Fact Sheet to the patient or the LTCF representative. SECTION E Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published or Dose 2 Clinician's signature: Title: If applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:	3a. Does this patient have	a high-risk medical cor	ndition?					□Yes □No
The Vaccine NDC matches the NDC on the bottom of this VAR form and the NDC on the patient leaflet. (Perform 3-way NDC match.) Initial here:	•	-						_
I have verified the Expiration Date is greater than today's date and have entered the Lot # and Expiration Date in the field below. Initial here:	The Vaccine NDC matche	s the NDC on the botton	n of this VAR form ar	nd the NDC	on the patient	leaflet. (Perform 3-way NE	C match.)	Initial here:
SECTION E Complete DURING the patient interaction I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. Initial here:						-	- 0	
I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. I have reviewed the Screening Questions and answers. Initial here: Initial here:	rnave vermed the Expirat	ion Date is greater trian	today's date and na	ave enteret	THE LOCH BIN	Expiration Date in the lic	nd Delow.	IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
I confirm(ed) the patient's Name, DOB and Requested Vaccine and verified it matches the information on the VAR form. I have reviewed the Screening Questions and answers. Initial here: Initial here:								
I have reviewed the Screening Questions and answers. I provided a EUA Fact Sheet to the patient or the LTCF representative. Initial here:	SECTION E Complete DUI	RING the patient intera	ection					
I have reviewed the Screening Questions and answers. I provided a EUA Fact Sheet to the patient or the LTCF representative. Initial here:	I confirm(ed) the patient's	Name, DOB and Requ	ested Vaccine and	verified it m	atches the info	rmation on the VAR form.		Initial here:
SECTION F Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration Clinician's name (print): Clinician's signature: f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:								Initial here:
SECTION F Complete AFTER vaccine administration Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published of Dose 2 Clinician's name (print): Gapplicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:								
Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published of Dose 2 Clinician's name (print): Clinician's signature: Title: Administration date: Date EUA Fact Sheet given to patient:	I provided a EUA Fact Sh	eet to the patient or the	LTCF representati	ve.			100 0000	Initial here:
Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published of Dose 2 Clinician's name (print): Clinician's signature: Title: Administration date: Date EUA Fact Sheet given to patient:	SECTION E					,		
Vaccine NDC Manufacturer Dosage Dose 1 Site of administration EUA Fact Sheet published of Dose 2 Title: Clinician's name (print): Clinician's signature: Title: Date EUA Fact Sheet given to patient: Date EUA Fact Sheet given to patient		dministration						
Clinician's name (print):Clinician's signature:Title: f applicable, intern/tech name (print):Administration date:Date EUA Fact Sheet given to patient:	Day by an area of the	A Family 7 Thomas	Manufacture	Dosage	□ Dose 1	Site of administration	FUA Es	ict Sheet published d
f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:	Vaccine	1100	Tyrania actaron	Docugo		Ollo of duffillification	LOTT	of Chibot persioner a
f applicable, intern/tech name (print): Administration date: Date EUA Fact Sheet given to patient:								
	Clinician's name (print):		Clinician's	signature:		Title	·:	
COVID-19 VACCINE LOT# COVID-19 VACCINE EXPIRATION DATE	f applicable, intern/tech na	me (print):	Adminis	tration da	te:	Date EUA Fact S	heet giver	to patient:
COVID-19 VACCINE LOT# COVID-19 VACCINE EXPIRATION DATE								
	COVID-19 VACCINE LOT#		COVID-19 VA	CCINE EXP	PIRATION DATE			

- Update the patient's record with any new allergy, health condition or primary care provider information.
 Enter vaccine lot #, expiration date and site of administration, then scan the VAR form into the patient's record.

FACT SHEET FOR RECIPIENTS AND CAREGIVERS

EMERGENCY USE AUTHORIZATION (EUA) OF THE PFIZER-BIONTECH COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 16 YEARS OF AGE AND OLDER

You are being offered the Pfizer-BioNTech COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to help you understand the risks and benefits of the Pfizer-BioNTech COVID-19 Vaccine, which you may receive because there is currently a pandemic of COVID-19.

The Pfizer-BioNTech COVID-19 Vaccine is a vaccine and may prevent you from getting COVID-19. There is no U.S. Food and Drug Administration (FDA) approved vaccine to prevent COVID-19.

Read this Fact Sheet for information about the Pfizer-BioNTech COVID-19 Vaccine. Talk to the vaccination provider if you have questions. It is your choice to receive the Pfizer-BioNTech COVID-19 Vaccine.

The Pfizer-BioNTech COVID-19 Vaccine is administered as a 2-dose series, 3 weeks apart, into the muscle.

The Pfizer-BioNTech COVID-19 Vaccine may not protect everyone.

This Fact Sheet may have been updated. For the most recent Fact Sheet, please see www.cvdvaccine.com.

WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE?

WHAT IS COVID-19?

COVID-19 disease is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

WHAT IS THE PFIZER-BIONTECH COVID-19 VACCINE?

The Pfizer-BioNTech COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. There is no FDA-approved vaccine to prevent COVID-19.

The FDA has authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine to prevent COVID-19 in individuals 16 years of age and older under an Emergency Use Authorization (EUA).

For more information on EUA, see the "What is an Emergency Use Authorization (EUA)?" section at the end of this Fact Sheet.

WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE PFIZER-BIONTECH COVID-19 VACCINE?

Tell the vaccination provider about all of your medical conditions, including if you:

- have any allergies
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have received another COVID-19 vaccine

WHO SHOULD GET THE PFIZER-BIONTECH COVID-19 VACCINE?

FDA has authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine in individuals 16 years of age and older.

WHO SHOULD NOT GET THE PFIZER-BIONTECH COVID-19 VACCINE?

You should not get the Pfizer-BioNTech COVID-19 Vaccine if you:

- had a severe allergic reaction after a previous dose of this vaccine
- had a severe allergic reaction to any ingredient of this vaccine

WHAT ARE THE INGREDIENTS IN THE PFIZER-BIONTECH COVID-19 VACCINE?

The Pfizer BioNTech COVID-19 Vaccine includes the following ingredients: mRNA, lipids ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 2 [(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.

HOW IS THE PFIZER-BIONTECH COVID-19 VACCINE GIVEN?

The Pfizer-BioNTech COVID-19 Vaccine will be given to you as an injection into the muscle.

The Pfizer-BioNTech COVID-19 Vaccine vaccination series is 2 doses given 3 weeks apart.

If you receive one dose of the Pfizer-BioNTech COVID-19 Vaccine, you should receive a second dose of this same vaccine 3 weeks later to complete the vaccination series.

HAS THE PFIZER-BIONTECH COVID-19 VACCINE BEEN USED BEFORE?

The Pfizer-BioNTech COVID-19 Vaccine is an unapproved vaccine. In clinical trials, approximately 20,000 individuals 16 years of age and older have received at least 1 dose of the Pfizer-BioNTech COVID-19 Vaccine.

WHAT ARE THE BENEFITS OF THE PFIZER-BIONTECH COVID-19 VACCINE? In an ongoing clinical trial, the Pfizer-BioNTech COVID-19 Vaccine has been shown to prevent COVID-19 following 2 doses given 3 weeks apart. The duration of protection against COVID-19 is currently unknown.

WHAT ARE THE RISKS OF THE PFIZER-BIONTECH COVID-19 VACCINE? Side effects that have been reported with the Pfizer-BioNTech COVID-19 Vaccine include:

- injection site pain
- tiredness
- headache
- muscle pain
- chills
- joint pain
- fever
- injection site swelling
- injection site redness
- nausea
- feeling unwell
- swollen lymph nodes (lymphadenopathy)

There is a remote chance that the Pfizer-BioNTech COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Pfizer-BioNTech COVID-19 Vaccine. Signs of a severe allergic reaction can include:

- Difficulty breathing
- Swelling of your face and throat
- A fast heartbeat
- A bad rash all over your body
- Dizziness and weakness

These may not be all the possible side effects of the Pfizer-BioNTech COVID-19 Vaccine. Serious and unexpected side effects may occur. Pfizer-BioNTech COVID-19 Vaccine is still being studied in clinical trials.

WHAT SHOULD I DO ABOUT SIDE EFFECTS?

If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.

Report vaccine side effects to **FDA/CDC Vaccine Adverse Event Reporting System (VAERS)**. The VAERS toll-free number is 1-800-822-7967 or report online to https://vaers.hhs.gov/reportevent.html. Please include "Pfizer-BioNTech COVID-19 Vaccine EUA" in the first line of box #18 of the report form.

In addition, you can report side effects to Pfizer Inc. at the contact information provided below.

Website	Fax number	Telephone number
www.pfizersafetyreporting.com	1-866-635-8337	1-800-438-1985

WHAT IF I DECIDE NOT TO GET THE PFIZER-BIONTECH COVID-19 VACCINE? It is your choice to receive or not receive the Pfizer-BioNTech COVID-19 Vaccine. Should you decide not to receive it, it will not change your standard medical care.

ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES PFIZER-BIONTECH COVID-19 VACCINE?

Currently, there is no approved alternative vaccine available for prevention of COVID-19. FDA may allow the emergency use of other vaccines to prevent COVID-19.

CAN I RECEIVE THE PFIZER-BIONTECH COVID-19 VACCINE WITH OTHER VACCINES?

There is no information on the use of the Pfizer-BioNTech COVID-19 Vaccine with other vaccines.

WHAT IF I AM PREGNANT OR BREASTFEEDING?

If you are pregnant or breastfeeding, discuss your options with your healthcare provider.

WILL THE PFIZER-BIONTECH COVID-19 VACCINE GIVE ME COVID-19?

No. The Pfizer-BioNTech COVID-19 Vaccine does not contain SARS-CoV-2 and cannot give you COVID-19.

KEEP YOUR VACCINATION CARD

When you get your first dose, you will get a vaccination card to show you when to return for your second dose of Pfizer-BioNTech COVID-19 Vaccine. Remember to bring your card when you return.

ADDITIONAL INFORMATION

If you have questions, visit the website or call the telephone number provided below.

To access the most recent Fact Sheets, please scan the QR code provided below.

Global website	Telephone number
www.cvdvaccine.com	
	1-877-829-2619 (1-877-VAX-CO19)

HOW CAN I LEARN MORE?

- Ask the vaccination provider.
- Visit CDC at https://www.cdc.gov/coronavirus/2019-ncov/index.html.
- Visit FDA at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization.
- Contact your local or state public health department.

WHERE WILL MY VACCINATION INFORMATION BE RECORDED?

The vaccination provider may include your vaccination information in your state/local jurisdiction's Immunization Information System (IIS) or other designated system. This will ensure that you receive the same vaccine when you return for the second dose. For more information about IISs visit: https://www.cdc.gov/vaccines/programs/iis/about.html.

WHAT IS THE COUNTERMEASURES INJURY COMPENSATION PROGRAM?

The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses of certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov/cicp/ or call 1-855-266-2427.

WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)?

The United States FDA has made the Pfizer-BioNTech COVID-19 Vaccine available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.

The Pfizer-BioNTech COVID-19 Vaccine has not undergone the same type of review as an FDA-approved or cleared product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives. In addition, the FDA decision is based on the totality of scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19

5

pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product. All of these criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic.

The EUA for the Pfizer-BioNTech COVID-19 Vaccine is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of these products, unless terminated or revoked (after which the products may no longer be used).



Manufactured for BioNTech Manufacturing GmbH An der Goldgrube 12 55131 Mainz, Germany

LAB-1451-0.7

Revised: December 2020



Scan to capture that this Fact Sheet was provided to vaccine recipient for the electronic medical records/immunization information systems.

Barcode Date: 12/2020

FACT SHEET FOR RECIPIENTS AND CAREGIVERS EMERGENCY USE AUTHORIZATION (EUA) OF THE MODERNA COVID-19 VACCINE TO PREVENT CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIVIDUALS 18 YEARS OF AGE AND OLDER

You are being offered the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2. This Fact Sheet contains information to help you understand the risks and benefits of the Moderna COVID-19 Vaccine, which you may receive because there is currently a pandemic of COVID-19.

The Moderna COVID-19 Vaccine is a vaccine and may prevent you from getting COVID-19. There is no U.S. Food and Drug Administration (FDA) approved vaccine to prevent COVID-19.

Read this Fact Sheet for information about the Moderna COVID-19 Vaccine. Talk to the vaccination provider if you have questions. It is your choice to receive the Moderna COVID-19 Vaccine.

The Moderna COVID-19 Vaccine is administered as a 2-dose series, 1 month apart, into the muscle.

The Moderna COVID-19 Vaccine may not protect everyone.

This Fact Sheet may have been updated. For the most recent Fact Sheet, please visit www.modernatx.com/covid19vaccine-eua.

WHAT YOU NEED TO KNOW BEFORE YOU GET THIS VACCINE

WHAT IS COVID-19?

COVID-19 is caused by a coronavirus called SARS-CoV-2. This type of coronavirus has not been seen before. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory illness that can affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever or chills; cough; shortness of breath; fatigue; muscle or body aches; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting; diarrhea.

WHAT IS THE MODERNA COVID-19 VACCINE?

The Moderna COVID-19 Vaccine is an unapproved vaccine that may prevent COVID-19. There is no FDA-approved vaccine to prevent COVID-19.

The FDA has authorized the emergency use of the Moderna COVID-19 Vaccine to prevent COVID-19 in individuals 18 years of age and older under an Emergency Use Authorization (EUA).

For more information on EUA, see the "What is an Emergency Use Authorization (EUA)?" section at the end of this Fact Sheet.

Revised: 12/2020

WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE MODERNA COVID-19 VACCINE?

Tell your vaccination provider about all of your medical conditions, including if you:

- have any allergies
- have a fever
- have a bleeding disorder or are on a blood thinner
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have received another COVID-19 vaccine

WHO SHOULD GET THE MODERNA COVID-19 VACCINE?

FDA has authorized the emergency use of the Moderna COVID-19 Vaccine in individuals 18 years of age and older.

WHO SHOULD NOT GET THE MODERNA COVID-19 VACCINE?

You should not get the Moderna COVID-19 Vaccine if you:

- had a severe allergic reaction after a previous dose of this vaccine
- had a severe allergic reaction to any ingredient of this vaccine

WHAT ARE THE INGREDIENTS IN THE MODERNA COVID-19 VACCINE?

The Moderna COVID-19 Vaccine contains the following ingredients: messenger ribonucleic acid (mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose.

HOW IS THE MODERNA COVID-19 VACCINE GIVEN?

The Moderna COVID-19 Vaccine will be given to you as an injection into the muscle.

The Moderna COVID-19 Vaccine vaccination series is 2 doses given 1 month apart.

If you receive one dose of the Moderna COVID-19 Vaccine, you should receive a second dose of the same vaccine 1 month later to complete the vaccination series.

HAS THE MODERNA COVID-19 VACCINE BEEN USED BEFORE?

The Moderna COVID-19 Vaccine is an unapproved vaccine. In clinical trials, approximately 15,400 individuals 18 years of age and older have received at least 1 dose of the Moderna COVID-19 Vaccine.

WHAT ARE THE BENEFITS OF THE MODERNA COVID-19 VACCINE?

In an ongoing clinical trial, the Moderna COVID-19 Vaccine has been shown to prevent COVID-19 following 2 doses given 1 month apart. The duration of protection against COVID-19 is currently unknown.

Revised: 12/2020 2

WHAT ARE THE RISKS OF THE MODERNA COVID-19 VACCINE?

Side effects that have been reported with the Moderna COVID-19 Vaccine include:

- Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness
- General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, and fever

There is a remote chance that the Moderna COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Moderna COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

- Difficulty breathing
- Swelling of your face and throat
- A fast heartbeat
- A bad rash all over your body
- Dizziness and weakness

These may not be all the possible side effects of the Moderna COVID-19 Vaccine. Serious and unexpected side effects may occur. The Moderna COVID-19 Vaccine is still being studied in clinical trials.

WHAT SHOULD I DO ABOUT SIDE EFFECTS?

If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.

Report vaccine side effects to FDA/CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to https://vaers.hhs.gov/reportevent.html. Please include "Moderna COVID-19 Vaccine EUA" in the first line of box #18 of the report form.

In addition, you can report side effects to ModernaTX, Inc. at 1-866-MODERNA (1-866-663-3762).

You may also be given an option to enroll in **v-safe**. **V-safe** is a new voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID-19 vaccination. **V-safe** asks questions that help CDC monitor the safety of COVID-19 vaccines. **V-safe** also provides second-dose reminders if needed and live telephone follow-up by CDC if participants report a significant health impact following COVID-19 vaccination. For more information on how to sign up, visit: www.cdc.gov/vsafe.

Revised: 12/2020

3

WHAT IF I DECIDE NOT TO GET THE MODERNA COVID-19 VACCINE?

It is your choice to receive or not receive the Moderna COVID-19 Vaccine. Should you decide not to receive it, it will not change your standard medical care.

ARE OTHER CHOICES AVAILABLE FOR PREVENTING COVID-19 BESIDES MODERNA COVID-19 VACCINE?

Currently, there is no FDA-approved alternative vaccine available for prevention of COVID-19. Other vaccines to prevent COVID-19 may be available under Emergency Use Authorization.

CAN I RECEIVE THE MODERNA COVID-19 VACCINE WITH OTHER VACCINES?

There is no information on the use of the Moderna COVID-19 Vaccine with other vaccines.

WHAT IF I AM PREGNANT OR BREASTFEEDING?

If you are pregnant or breastfeeding, discuss your options with your healthcare provider.

WILL THE MODERNA COVID-19 VACCINE GIVE ME COVID-19?

No. The Moderna COVID-19 Vaccine does not contain SARS-CoV-2 and cannot give you COVID-19.

KEEP YOUR VACCINATION CARD

When you receive your first dose, you will get a vaccination card to show you when to return for your second dose of the Moderna COVID-19 Vaccine. Remember to bring your card when you return.

ADDITIONAL INFORMATION

If you have questions, visit the website or call the telephone number provided below.

To access the most recent Fact Sheets, please scan the QR code provided below.

Moderna COVID-19 Vaccine website	Telephone number
www.modernatx.com/covid19vaccine-eua	1-866-MODERNA
	(1-866-663-3762)

HOW CAN I LEARN MORE?

- Ask the vaccination provider
- Visit CDC at https://www.cdc.gov/coronavirus/2019-ncov/index.html
- Visit FDA at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
- Contact your state or local public health department

Revised: 12/2020 4

WHERE WILL MY VACCINATION INFORMATION BE RECORDED?

The vaccination provider may include your vaccination information in your state/local jurisdiction's Immunization Information System (IIS) or other designated system. This will ensure that you receive the same vaccine when you return for the second dose. For more information about IISs, visit: https://www.cdc.gov/vaccines/programs/iis/about.html.

WHAT IS THE COUNTERMEASURES INJURY COMPENSATION PROGRAM?

The Countermeasures Injury Compensation Program (CICP) is a federal program that may help pay for costs of medical care and other specific expenses of certain people who have been seriously injured by certain medicines or vaccines, including this vaccine. Generally, a claim must be submitted to the CICP within one (1) year from the date of receiving the vaccine. To learn more about this program, visit www.hrsa.gov/cicp/ or call 1-855-266-2427.

WHAT IS AN EMERGENCY USE AUTHORIZATION (EUA)?

The United States FDA has made the Moderna COVID-19 Vaccine available under an emergency access mechanism called an EUA. The EUA is supported by a Secretary of Health and Human Services (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.

The Moderna COVID-19 Vaccine has not undergone the same type of review as an FDA-approved or cleared product. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, and available alternatives. In addition, the FDA decision is based on the totality of the scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product. All of these criteria must be met to allow for the product to be used during the COVID-19 pandemic.

The EUA for the Moderna COVID-19 Vaccine is in effect for the duration of the COVID-19 EUA declaration justifying emergency use of these products, unless terminated or revoked (after which the products may no longer be used).

©2020 ModernaTX, Inc. All rights reserved.

Patent(s): www.modernatx.com/patents

Revised: 12/2020



Scan to capture that this Fact Sheet was provided to vaccine recipient for the electronic medical records/immunization information systems.

Barcode Date: 12/2020

Revised: 12/2020 5



COVID-19 (Coronavirus Disease)













WEAR A MASK

STAY 6 FEET APART

Importance of COVID-19 Vaccination for Residents of Longterm Care Facilities

Updated Dec. 13, 2020



Based on recommendations from the Advisory Committee on Immunization Practices (ACIP), an independent panel of medical and public health experts, CDC recommends residents of long-term care facilities be included among those offered the first supply of COVID-19 vaccines.

Vaccinating LTCF residents will save lives

Making sure LTCF residents can receive COVID-19 vaccination as soon as vaccines are available will help save the lives of those who are most at risk of dying from COVID-19. According to ACIP's recommendations, long-term care facility residents include adults who reside in facilities that provide a range of services, including medical and personal care, to persons who are unable to live independently. The communal nature of LTCFs and the population served (generally older adults often with underlying medical conditions) puts facility residents at increased risk of infection and severe illness from COVID-19. By November 6, 2020, approximately 569,000–616,000 COVID-19 cases and 91,500 deaths were reported among LTCF residents and staff members in the United States, accounting for 39% of deaths nationwide.

Benefits of vaccination believed to outweigh possible risks

All COVID-19 vaccines were tested in clinical trials involving tens of thousands of people to make sure they meet safety standards and protect adults of different races, ethnicities, and ages, including adults over the age of 65. There were no serious safety concerns. The most common side effects were pain at the injection site and signs and symptoms like fever and chills. After a review of all the available information, ACIP and CDC agreed the lifesaving benefits of COVID-19 vaccination for LTCF residents outweigh the risks of possible side effects.

The safety of COVID-19 vaccines is a top priority

To help make important unapproved medical products, including vaccines, available quickly during the COVID-19 pandemic, the US Food and Drug Administration (FDA) can use what is known as an Emergency Use Authorization (EUA) 🔀 . Before any vaccine can be authorized for use under an EUA, FDA must determine that the vaccine's benefits outweigh possible risks.

Once people begin receiving COVID-19 vaccinations, CDC and FDA will monitor vaccine safety closely. The United States will use existing robust systems and data sources to conduct ongoing safety monitoring. An additional layer of safety monitoring has also been added that allows CDC and FDA to evaluate COVID-19 vaccine safety almost immediately. Learn more about COVID-19 vaccine safety monitoring

For LTCFs in particular, CDC will work with pharmacies and other partners to report possible side effects (called adverse events) to the Vaccine Adverse Event Reporting System (VAERS) 🖸 . Facility staff and residents' families are encouraged to also report any adverse events immediately.

CDC will work with pharmacies and other partners to provide communication materials to help LTCFs educate residents and their families about the vaccine, answer their questions about vaccine safety and other issues, and prepare them for vaccination clinics. For some COVID-19 vaccines, two shots are needed to provide the best protection, and the shots are given several weeks apart. Each recipient or caregiver will receive a vaccination record card to ensure they receive the correct vaccine for the second dose.

Risks and benefits will be explained to everyone offered a COVID-19 vaccination

Explaining the risks and benefits of any treatments to a patient in a way that they understand is the standard of care. In LTCFs, consent or assent for vaccination should be obtained from residents (or the person appointed to make medical decisions on their behalf) and documented in the resident's chart per standard practice.

For LTCFs participating in the Federal Pharmacy Partnership for Long-term Care Program, pharmacies will work directly with LTCFs to ensure staff and residents who receive the vaccine also receive an EUA fact sheet before vaccination. The EUA fact sheet explains the risks and benefits of the COVID-19 vaccine they are receiving and what to expect. Each LTCF resident's medical chart must note that this information was provided to the resident. If a resident is unable to make medical decisions due to decreased mental capacity or illness, the EUA fact sheet will be provided to the person appointed to make medical decisions on their behalf (the medical proxy or power of attorney).

Last Updated Dec. 13, 2020